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PQUARTERLY FOCUS ISSUE: HEART FAILURE Editorial Comment
Is Rehospitalization After Heart Failure Admission
a Marker of Poor Quality?
Time for Re-Evaluation*
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sn the U.S., there are over 1 million hospitalizations for
eart failure annually (1–3). This number appears to be
ncreasing each year and equally affecting men and women.
ehospitalization following heart failure admissions re-
ains high, with recent reports from the Centers for
edicaid and Medicare Services suggesting that hospital-
zation rates may approach 25% at 30 days, and this may
xceed 50% in some health systems (4–8). In addition,
ecurrent hospitalization following heart failure admission
nd myocardial infarction admission have become indicators
f quality outcomes (9). Report cards for hospitals in the
.S. that care for Medicare patients have been publicly
eported and highlighted in the media and public Websites.
ome of the top 10 heart centers in the U.S. had low 30-day
ortality rates, but higher than average rehospitalization
ates (7). This raises the question as to whether rehospital-
zation following a heart failure admission is an appropriate
ndicator of quality for the health system.
See page 362
In this issue of the Journal, Heidenreich et al. (10) provide
aluable new insights into why rehospitalization is not a
arker of poor quality following heart failure admission at
0 days. This report from the Veterans Affairs (VA) Health
ystem shows an important divergence from 2002 to 2006,
n which mortality rates decreased at 30 days and 1 year, yet
ehospitalization rates have remained stable. On first look,
ne might conclude that the healthcare administrators in
he VA system have performed with mixed results with an
A” for mortality reduction and a “C–” for rehospitalization
ates. However, an in-depth analysis of the VA report
ndicates this may be far from the truth, based on several
mportant findings.
First, the mortality rate reduction over the 5-year period
as approximately 40% in-hospital, 30% at 30 days, and
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.B
From the Duke University Medical Center, and the Duke Clinical Research
nstitute, Durham, North Carolina.0% by 1 year. Mortality rates reported are consistent with
he national rates of mortality seen in large U.S. registries
11–13). Although some parameters suggest a decreasing
isk over time based on laboratory assessments, other factors
ncreased over time, such as diabetes, kidney disease, atrial
brillation, hypertension, and depression, conferring a
eightened risk of rehospitalization or death. Indeed, the
orsening Charlson index is consistent with increasing
omorbidities over the study period.
Why was there this apparent improvement in mortality
ates? First, investigators demonstrate excellent improve-
ent in use of evidence-based therapies such as beta-
lockers and angiotensin-converting enzyme inhibitors,
oth of which have been shown to be associated with
mproved outcome following hospitalization (1,2,14–17).
ates of implantable cardioverter-defibrillator use and pace-
aker therapy also increased, potentially improving the
urvival rates (18). In addition, rates of coronary angiogra-
hy increased, which may have led to better medical
anagement of ischemic heart disease. Proper identifica-
ion, shorter lengths of stay, and greater rates of early
ollow-up at 14 days may have led to fewer in-hospital
omplications such as infections and earlier detection of
mpending decompensation.
Is there room for improvement? Clearly the use of
vidence-based beta-blockers was low, and the use of
ldosterone antagonists, believed to have an early mortality
dvantage (19–21), are not reported. Despite these short-
omings, the VA health system has demonstrated a remark-
ble improvement in mortality over time.
Now, let us examine the rehospitalization rates and why
hey did not decrease over time. Why should we expect
hem to decrease? As noted previously, the patient popula-
ion over time became sicker with a higher comorbidity
ndex and an important increase in several comorbidities.
ortality rates in-hospital dropped significantly by approx-
mately 40%, in the face of an important 1-day reduction in
ength of stay. We, therefore, believe that sicker patients
ho were likely to die in 2002 remained alive in 2006, living
ith comorbidities and a higher class of heart failure
ymptoms, resulting in greater exposure to rehospitalization.
ecause of the shorter length of stay and heightened
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Survival and Readmission Following Hospitalization July 27, 2010:369–71urveillance at 14 days, patients were hospitalized at a 20%
reater rate at 30 days, perhaps averting death. In fact, a
etter indicator of health care costs and utilization would be
he total hospital days alive over the 30-day period. As seen
rom the report by Heidenreich et al. (10), this was not
ncreased over the 5-year period.
Can we learn from the single-payer VA Health System?
he VA Health System has several advantages over current
ealth systems in the U.S. First, it has a remarkable
nformation system that is uniform across hospitals. Patients
ischarged from 1 hospital and readmitted to a different VA
ospital have immediate and adequate information regard-
ng the patient’s history and previous medical course.
econd, health care providers are part of a centralized
eporting system that provides standardized guidance on
uality initiatives and feedback in a timely fashion. Third, a
arge centralized database allows for modeling and analytical
uidance for strategic initiatives to help physicians improve
utcomes. Finally, health care providers are employed in the
A system, and therefore aligned with the hospitals and
linics to improve outcomes and contain costs.
Where does quality assessment of rehospitalization fol-
owing heart failure admission stand? The following is
roposed: If a health system/hospital has a low mortality
ate in this population, they should receive no deduction on
uality if there is an increase in rehospitalization rates, as
his may be one of the strategies for improving outcome. If,
owever, the mortality rate is high, and the rehospitalization
ate is high, this should signal quality deficiencies and
ncreased scrutiny. An alternative proposal should be that
otal hospital days alive over a 30-day period should be the
arker of quality following heart failure hospitalization.
his recommendation is based on data from large clinical
rials or registries suggesting an inverse relationship between
nitial length of stay and 30-day rehospitalization rates (12).
his is intuitive for the regions of the world in which the
verage length of stay for heart failure is up to 20 days,
llowing only 10 potential at-risk days for rehospitalization
22,23). In contrast, health systems that have responded to
conomic pressures and have reduced the length of stay to 5
ays for heart failure, as in the U.S., have the highest 30-day
ehospitalization rates (5,7,24). One reason may be that in
he U.S., one-third of patients still have signs and symptoms
f congestion at discharge, putting them at heightened risk
or rehospitalization (14,25). Perhaps a day longer in the
nitial hospital stay would reduce the risk of rehospitaliza-
ion at 30 days.
One thing is certain: Rehospitalization after heart failure
dmission is complex, multifactorial, and not clearly related
o quality.
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